Nama's AI scorecard currently rates Twist Bioscience Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does TWST report earnings?

Twist Bioscience's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$0.20.

What is the TWST price target?

The median analyst price target from 12 analysts is $188.50, with a range of $45.00 – $215.00.

Is TWST Shariah compliant?

Nama's AAOIFI-style screen reads Twist Bioscience as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Twist Bioscience (TWST)

Healthcare · Diagnostics Research · NASDAQ

Twist Bioscience (TWST) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $8.01B and a free-cash-flow yield of -1.0%. Over the most recent reported fiscal year, revenue grew 20.3%. Nama's AI scorecard rates it Sell, 2.8 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 2.8/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Leading · +408.2% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-45.0%

How far the last close sits under the highest price of the past five years.

Market cap	$8.01B
Trailing P/E	—
Price / book	17.0
Price / sales	18.6
FCF yield	-1.0%
Dividend yield	—
Gross margin	52.0%
Operating margin	-31.9%
Net margin	-31.7%
Revenue growth (YoY)	+20.3%
Revenue growth (3-yr annual)	+22.8%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

TWST earnings

Next report: Nov 12, 2026 (Q4 2026, EPS estimate -$0.20). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Aug 3, 2026	-$0.56	-$0.28	-100.0%	$118.38M
Q2 2026	May 4, 2026	-$0.60	-$0.53	-13.2%	$110.72M
Q1 2026	Feb 2, 2026	-$0.50	-$0.52	+3.9%	$103.70M
Q4 2025	Nov 14, 2025	-$0.45	-$0.50	+10.0%	$99.01M

TWST analyst price target

Median target $188.50 from 12 analysts, ranging $45.00 – $215.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2

Explore live TWST data on Nama Insights →

TWST FAQ

Is TWST a buy?: Nama's AI scorecard currently rates Twist Bioscience Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does TWST report earnings?: Twist Bioscience's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$0.20.
What is the TWST price target?: The median analyst price target from 12 analysts is $188.50, with a range of $45.00 – $215.00.
Is TWST Shariah compliant?: Nama's AAOIFI-style screen reads Twist Bioscience as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.